ReGen Biologics' CE-marks CMI (Collagen Meniscus Implant) implant:
This article was originally published in Clinica
Executive Summary
ReGen Biologics has CE-marked its Collagen Meniscus Implant (CMI) system. Franklin Lakes, New Jersey-based ReGen is preparing to launch the CMI in Europe through its existing distribution partnership with SulzerMedica. The CMI system is used in treating tears of the meniscus of the knee and is a resorbable collagen scaffold designed to prevent or delay progressive degenerative changes in the knee joint by acting as surrogate meniscus material subsequent to a partial meniscectomy.